New drug KBP-5074 takes first step: safety check in healthy people
NCT ID NCT02228733
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and how the body processes different doses of KBP-5074 in 46 healthy adults. Researchers also looked at how food affects drug levels. The results will help choose the right doses for future studies in patients with kidney disease and high blood pressure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KBP-5074
- What this could lead to
- If successful, this study will help determine safe doses for future trials testing whether KBP-5074 can slow kidney disease and control high blood pressure.
- What could go wrong
- This is an early Phase 1 safety study in only 46 healthy people. It does not test whether the drug actually treats any disease, and results may not predict effects in patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test